The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids

Gut

Volumn 56, Issue 12, 2007, Pages 1743-1746

  Forrest, Ewan H ^a   Morris, A J ^a   Stewart, S ^b   Phillips, M ^c   Oo, Y H ^d   Fisher, N C ^e   Haydon, G ^d   O'Grady, J ^c   Day, C P ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; GLASGOW OUTCOME SCALE; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; GLUCOCORTICOIDS; HEPATITIS, ALCOHOLIC; HUMANS; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36749037643     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.099226     Document Type: Article

References (11)

1. Carithers JRL, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 1989;110:85-690.
2. Forrest EH, Evans CDJ, Stewart S, et al. Analysis of factors related to mortality in alcoholic hepatitis and the derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174-9.
3. Morgan M. The treatment of alcoholic hepatitis. Alc Alcoholism 1996;31:117-34.
4. Christensen E. Alcoholic hepatitis - glucocorticoids or not? J Hepatol 2002;36:547-8.
5. Mathurin P, Mendenhall CL, Carithers J, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-7.
6. McCullough AJ, O'Connor JFB. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022-36.
7. Stewart SF, Prince M, Bassendine MF, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007;47:277-83.
8. Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial. J Hepatol 2006;44:784-90.
9. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2.
10. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41:353-8.
11. Srikureja W, Kyulo NL, Runyon BA, et al. MELD is a better prognostic model than the Child-Turcotte-Pugh score or Discriminant Function in patients with alcoholic hepatitis. J Hepatol 2005;42:700-6.